Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

Gerd R Burmester,Antonio Gómez-Centeno,Claudia Pena-Rossi,Mark C Genovese,Gregory St John,Karthinathan Thangavelu,Susan Boklage,Leon Gervitz,Vibeke Strand,Andrea Rubbert-Roth,Howard Amital,Tatiana Raskina

doi:10.1136/rmdopen-2019-001017

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

Gerd R Burmester, Antonio Gómez-Centeno + Show 10 more

Open Access

https://doi.org/10.1136/rmdopen-2019-001017

Copy DOI

Journal: RMD Open	Publication Date: Oct 1, 2019
Citations: 9	License type: open-access

Affiliation: Hospital Universitari de Vic, Parc Taulí Hospital Universitari, Stanford University, Stanford Medicine, Regeneron (United States), Sanofi (United States), Kantonsspital St. Gallen, Sheba Medical Center

#Open-label Extension Week #Sarilumab Monotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveEvaluate open-label sarilumab monotherapy in patients with rheumatoid arthritis switching from adalimumab monotherapy in MONARCH (NCT02332590); assess long-term safety and efficacy in patients continuing sarilumab during open-label extension (OLE).MethodsDuring the...

Full Text